medwireNews: Inflammatory bowel disease (IBD) is an “uncommon” occurrence among patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), or psoriasis who are treated with the interleukin (IL)-17A inhibitor secukinumab, researchers report.
The pooled analysis included a total of 7355 patients from 21 clinical trials with a cumulative secukinumab exposure of 16,2260.9 patient–years. In all, three of 1380 patients with PsA developed ulcerative colitis, three developed Crohn’s disease, and unclassified IBD was reported in two patients, giving exposure-adjusted incidence rates (IRs) of 0.08, 0.08, and 0.05 per 100 patient–years, respectively.
Similarly, the corresponding exposure-adjusted IRs were 0.2, 0.4, and 0.1 per 100 patient–years for the 794 patients with AS, and 0.13, 0.05, and 0.01 per 100 person–years for the 5181 patients with psoriasis.
These rates “appear to be within the range of expected background IRs” for patients with PsA, AS, and psoriasis, and “did not increase over time,” write Stefan Schreiber (Christian-Alrechts-University, Kiel, Germany) and fellow researchers in the Annals of the Rheumatic Diseases.
They note, however, that given previous reports of IBD exacerbations in patients treated with secukinumab, “[c]aution is recommended when prescribing IL-17 inhibitors to patients with active IBD in the special warnings section of the summary of product characteristics for secukinumab and these patients should be followed closely.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group
See also:
- FUTURE 5 supports subcutaneous secukinumab for PsA
- Secukinumab boosts chances of minimal disease activity for PsA patients
- Secukinumab provides ‘rapid and sustained’ pain relief for PsA patients
- Low rates of radiographic progression with secukinumab treatment in PsA patients
- FUTURE 1 extension results support secukinumab as a long-term treatment option for PsA
- Very early intervention with secukinumab may be a feasible approach in PsA
- Further evidence for the benefits of secukinumab in AS patients
- Secukinumab treatment does not compromise systemic immune response in SpA patients
- Elevated CRP levels may point to better secukinumab response in AS patients